The report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Cancer immunotherapy market is expected to grow at a healthy CAGR of 13.5% from 2022 to 2027.
Request a Sample here: https://www.stratviewresearch.com/Request-Sample/2880/cancer-immunotherapy-market.html#form
Segment Analysis
Based on the drugs class type, the market is bifurcated into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, cell therapies, immunomodulators, and interferons alpha. Monoclonal antibodies held the major share of the market in 2021, and are expected to remain the biggest demand generator for the cancer immunotherapy market in the foreseen future. Key factors such as cost effectiveness and increasing investments in R&D of monoclonal antibodies are expected to drive the market growth in the coming years.
Based on the diagnosis type, the market is segmented as lung cancer, breast cancer, multiple myeloma, colorectal cancer, head & neck cancer, prostate cancer, melanoma, and other cancer types. Lung cancer captured the largest share of the cancer immunotherapy market in 2021, due to factors such as increasing number of patients suffering from lung diseases. The segment is likely to remain dominant during the forecast period, owing to the growing awareness of the early therapeutics of lung cancer.
Based on the end-user type, the market is segmented as hospitals, clinics, and others. Among these end-user types, hospital dominates the market and is expected to grow with the highest CAGR during the forecast period. Hospitals are highly preferred for cancer immunotherapy, and rising demand for cancer immunotherapy in hospitals is expected to drive the market growth over the forecast period.
In terms of regions, North America is expected to remain the largest market for cancer immunotherapy over the forecast period. Major factors such as rising incidence of cancer, increasing demand for modern cancer therapeutics, and growing geriatric population are fuelling the growth of the regional cancer immunotherapy market. Asia-Pacific is expected to be the fastest-growing region during the forecast period, due to rise in healthcare expenditure, development in healthcare infrastructure, increasing prevalence of cancer, and rising per capita income.
The cancer immunotherapy market is segmented into the following categories:
Features of the Report
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools.
The Cancer Immunotherapy Market analysis report discusses the following heads in great detail:
About Stratview Research
Stratview Research is a trusted brand globally, providing high quality research and strategic insights that help companies worldwide in effective decision making. It is a global market intelligence firm providing a wide range of services including syndicated market reports, custom research, and sourcing intelligence across industries, such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas.
Contact: Stratview Research
E-mail: [email protected]
Direct: +1-313-307-4176
No Comments
Leave a comment Cancel